We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent investor discussions on ADVFN regarding Cambridge Nutritional Sciences Plc (CNSL) reveal a generally positive sentiment surrounding the stock, with many participants expressing confidence in its potential for growth. Notably, analysts have observed significant trading activity and suggest that current prices present a bargain. One user, wbodger, speculated about potential shorting strategies, implying that investors are maneuvering for advantageous positions amid the recent fluctuation in stock price.
Financial highlights discussed include CNSL's low market capitalization of approximately £8 million, substantial cash reserves of £5 million, and annual revenues around £10 million, which signify a profitable business model with strong margins. The recurring mention of target prices, with one analyst predicting a rise to 5p by February's end and brokers maintaining a target of 10p per share, indicates a bullish outlook among investors. There is particular focus on recent director purchases as a signal of confidence, as noted by thecoyone who observed the stock's rise post-settlement of a significant cash recovery. One compelling quote from silverspoon2009 summarizes the sentiment: “The entire business is in for nothing and it's generating £10m revenues per year, growing, profitable and excellent margins.”
Show more
Cambridge Nutritional Sciences Plc (CNSL), focused on medical diagnostics and personalized health and nutrition, recently reported a significant development concerning its shareholding. On February 5, 2025, Carolyn Rand, the Non-Executive Chair of the Company, purchased 100,000 ordinary shares at a price of 3.59 pence each. Following this acquisition, Rand's total beneficial holding now stands at 197,500 shares, which represents approximately 0.08% of the company's issued share capital.
This transaction could signal confidence in the company’s future, as insider buying typically reflects positive sentiments from executives regarding the company's performance and prospects. As CNSL continues to engage in its mission in health diagnostics, monitoring shareholding patterns among key personnel such as board members could be indicative of the company's strategic direction and investor sentiment.
Show more
Recovery play |
Have added today, can see a move back to 4p PDQ on a bit of volume, it's tough getting any stock however ! |
Buyers returning, market starting to factor in oversold technical's + strong 2nd half sales forecasts. |
That 1.8m off market buy has taken the overhang out entirely. |
Gentlemen |
The company has £5 million in the bank. This is an incredible debt free growing business. |
The pattern of late buying has been ongoing for a long time, usually batches of 100k/200k/300k shares. |
The company should pay the surplus cash to shareholders as a special dividend. That will drive up the share price by 50% instantly. |
Gentlemen |
Could this be a good time for a trade, the RSI sits at a 14 month low, the shares have fallen from 4.4p reached in July to 2.85p but on very low volume. |
Nothing bad in the recent presentation event of a few weeks ago to justify a near 20% fall since. |
There is no liquidity in the stock hence it can move disproportionally either way on thin volume. |
Anyone buying into this share will lose at least 11% because of the wide spread immediately. MMs don't do investors any favour. Long term investors only. |
Thank you thecoyone. |
Just watched the presentation, the team seem very happy with things generally, in respect of the DHSC claim still no movement however it appears they are being more dynamic in trying to conclude the matter, in a broker note today it was re-iterated that CNSL have no liability and are pursuing a significant counter claim. |
What has happened with the DHSC claim and counterclaim? Can someone kindly advice if it comes up at the Presentation. I am not available for 4pm |
Bid has now fallen from 3.6p at open to 3p on just £12k of sells. |
On the cash front , it is worth noting that Cavendish ( and indirectly CNSL's own budget forecasts ) is expecting £5m net cash at year end in March , 2025 . Whilst this is down £0.4m on last year's figure , it is all because of £0.6m extra capital expenditure this year , which the company is spending on system and process upgrades . |
Disappointing numbers for first 6 months. Not really seeing any growth at moment. Looks like we will have to wait another 6 months to see if they can actually meet expectations for full year with sustainable growth. Not surprised to see share price back to 3p. Very frustrating. |
The prediction about the share price was wrong unfortunately. |
Cavendish have re-iterated their target price of 10p a share this morning, suggest the company is moving towards a growth phase having now reorganised the business. |
Very positive results today with EBITDA profitable at half year which is usually their weakest period, cash was also ahead of H1 2023, margins improved again, suggestions of a strong 2nd half. |
Cavendish note this AM is suggesting revenues of £8.8m for the year to March , 2025 ( previously £9.4m ) but is maintaining its EBITDA forecast of £0.4m thanks to a near 3 percentage point improvement in gross margins . CNSL is continuing to invest in further operational improvements as well as sales & marketing despite the Q1 sales hiccup , which was all about destocking . |
I did not realise this outfit is being bashed hysterically over on LSE, that has to be a good sign, how can you bash a company that has exceeded market expectations over the last 12 months, has cash of £5m, is EBITDA profitable and valued at only £8.3m ? |
Just £3k of shares on offer with IG currently then they want a premium, a number of retail platforms are 'at best' on any size buy. |
Type | Ordinary Share |
Share ISIN | GB00B1VCP282 |
Sector | Offices-holdng Companies,nec |
Bid Price | 3.30 |
Offer Price | 3.75 |
Open | 3.65 |
Shares Traded | 316,323 |
Last Trade | 08:20:19 |
Low - High | 3.525 - 3.65 |
Turnover | 9.77M |
Profit | -231k |
EPS - Basic | -0.0010 |
PE Ratio | -35.20 |
Market Cap | 8.69M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads